retatrutide diabetes The power of three: Retatrutide's role in modern obesity and therapy ADA: Retatrutide Improves HbA1c in

Description

Particularly noteworthy is that in patients with both type 2 diabetes and MASLD, after 24 weeks of treatment with a 10 mg dose of efinopegdutide, liver fat content reduced by 72.7%, a result that is superior to the 42.3% reduction achieved with a 1 mg dose of semaglutide, despite a similar overall weight loss being observed with the two interventions

The most important intervention is ensuring adequate nutritional intake , particularly of protein

Both drugs use weekly injection pens

Its unique mechanism of action provides additional metabolic benefits, such as improved glucose control and appetite suppression, making it appealing for both weight loss and diabetes management